HomeBlogHLA-DQA1 Gene
Inflammation

HLA-DQA1: Celiac Disease Genetics, Gluten Sensitivity, and the DQ2/DQ8 Story

Celiac disease cannot develop without specific HLA gene combinations — primarily HLA-DQ2 or HLA-DQ8. These haplotypes encode the antigen-presenting proteins that bind deamidated gluten peptides and present them to CD4+ T cells, triggering the autoimmune cascade that destroys intestinal villi. Without the DQ2 or DQ8 configuration, even lifelong gluten consumption cannot initiate celiac disease. Having them confers susceptibility but not inevitability — only 3-5% of DQ2 carriers ever develop celiac disease.

Gnosis·Feb 27, 2026·8 min read

Key Haplotypes

HLA-DQ2.5 (DQA1*05:01 / DQB1*02:01 or DQB1*02:02)

Present in approximately 90% of celiac patients. The DQ2.5 heterodimer has the highest binding affinity for deamidated gluten peptides. Homozygous DQ2.5 (both chromosomes) confers approximately 5x higher celiac risk than heterozygous DQ2.5. Found in 25-30% of the general European population.

HLA-DQ8 (DQA1*03:01 / DQB1*03:02)

Present in approximately 5-10% of celiac patients. More common in Central European populations. Lower binding affinity than DQ2.5 for alpha-gliadin peptides; high affinity for different gliadin epitopes. DQ8 patients often have less severe intestinal damage at diagnosis.

HLA-DQ2.2 (DQA1*02:01 / DQB1*02:02)

Low-risk configuration on its own. However, DQ2.2 carriers who also carry the DQB1*02 allele on the other chromosome form a "trans DQ2" configuration that has intermediate celiac risk. This is often missed in simplified DQ2/DQ8 testing.

Neither DQ2 nor DQ8

Negative predictive value for celiac disease is essentially 100%. Standard clinical practice: a negative HLA result rules out celiac disease and makes lifelong restriction unnecessary for celiac prevention. Note: non-celiac gluten sensitivity may still occur independent of HLA status.

The Molecular Mechanism: Why HLA Matters

The HLA (Human Leukocyte Antigen) genes sit in the MHC (Major Histocompatibility Complex) region of chromosome 6 — the most polymorphic region in the human genome. HLA class II proteins (including DQ2 and DQ8) are expressed on antigen-presenting cells and present foreign peptide fragments to CD4+ helper T cells to initiate adaptive immune responses.

Gluten peptides — particularly specific sequences from alpha-gliadin, omega-gliadin, and glutenin proteins in wheat (and analogous proteins in rye and barley) — are normally too large to be immune-stimulating. The key step is tissue transglutaminase (tTG), an enzyme in the intestinal mucosa that deamidates specific glutamine residues in gluten peptides, converting them to glutamate. This deamidation dramatically increases the binding affinity of gluten peptides for DQ2 and DQ8 — which is why the immune system ignores raw gluten in most contexts but attacks deamidated gluten in the context of susceptible HLA.

Once a deamidated gluten peptide is bound to a DQ2 or DQ8 molecule and presented to CD4+ T cells, an inflammatory cascade begins: T cells activate B cells to produce anti-tTG autoantibodies, Th1 cytokines (TNF-α, IFN-γ) are released, and intraepithelial lymphocytes are recruited and activated. The result is villous atrophy — the flattening of intestinal villi that reduces absorptive surface area by up to 90% and causes the malabsorption characteristic of celiac disease.

The self-directed component (autoimmunity against tTG) is what makes celiac a true autoimmune disease rather than a food allergy. The antibodies and T cells target the body's own enzyme, which happens to be the same enzyme that processed the triggering peptide.

Celiac Disease Prevalence and the HLA Gap

The prevalence paradox of celiac disease is important to understand: HLA-DQ2/DQ8 haplotypes are present in approximately 30-40% of the general European population, yet celiac disease affects only 1-2% of the same population. This means that for every person who develops celiac, approximately 15-30 HLA-susceptible individuals do not.

The non-HLA factors that convert susceptibility to disease include:

  • Intestinal microbiome composition: Early life microbiome development appears to shape the regulatory T cell environment. A 2020 Nature study by Vatanen et al. found that specific gut bacterial communities at age 1-3 predicted later celiac development in genetically susceptible children.
  • Timing and amount of first gluten exposure: The ESPGHAN guidelines previously recommended introducing gluten at 4-6 months; evidence now suggests very early introduction (4-6 months) while still breastfeeding may be protective.
  • Viral infections: Reovirus infection and certain enteric viral infections have been shown to break oral tolerance to gluten in mouse models and are epidemiologically associated with celiac in human cohorts.
  • Zonulin and intestinal permeability: Gluten itself activates zonulin release (through the CXCR3 receptor), which transiently increases intestinal permeability — creating a self-amplifying cycle in susceptible individuals.
  • Non-HLA genetic factors: GWAS has identified 57+ non-HLA celiac risk loci, including variants in IL-2, IL-21, TAGAP, SH2B3, and others that modulate T cell activation and intestinal barrier function.

Clinical Testing: What to Test and When

HLA testing for DQ2/DQ8 is most valuable as a rule-out test. The diagnostic algorithm in practice:

Celiac Disease Testing Sequence

1.

Serology (blood test, on gluten-containing diet)

IgA anti-tissue transglutaminase (tTG-IgA) — sensitivity 93%, specificity 96%. Total IgA to rule out IgA deficiency. Anti-deamidated gliadin peptide (DGP) IgG if IgA deficient. Do not restrict gluten before this test.

2.

Endoscopy with duodenal biopsy (gold standard)

Required for definitive diagnosis in adults. Marsh scoring system classifies mucosal damage (Marsh 3a-3c = positive). Minimum 4 biopsies from different duodenal sites.

3.

HLA typing (DQ2/DQ8)

Used when: serology is equivocal, patient already on gluten-free diet, or to definitively exclude celiac in low-probability cases. Negative result eliminates celiac as a diagnosis with near 100% certainty. Positive result only confirms susceptibility, not disease.

The most common clinical error is testing HLA first and interpreting a positive DQ2 result as a celiac diagnosis. It is not. HLA-DQ2 positive + normal tTG antibodies + normal biopsy = no celiac disease, despite the susceptibility alleles.

Equally important: patients who have already eliminated gluten from their diet before testing will have falsely normal serology and potentially normal biopsies. The standard clinical recommendation is to complete a gluten challenge (2 slices of gluten-containing bread per day for at least 6 weeks) before serological testing if already gluten-free. HLA testing can be done at any time regardless of diet.

Non-Celiac Gluten Sensitivity: The HLA Picture

Non-celiac gluten sensitivity (NCGS) is a clinically recognized condition defined by gastrointestinal and extraintestinal symptoms that improve on a gluten-free diet but lack the autoimmune features and intestinal damage of celiac disease. It is not the same as wheat allergy (IgE-mediated) or celiac disease (IgA/T cell autoimmune).

The HLA picture in NCGS is substantially different from celiac: approximately 50% of NCGS patients carry DQ2 or DQ8, compared to over 99% of celiac patients. This means roughly half of NCGS patients have no HLA susceptibility for celiac — their immune system cannot form the DQ2/DQ8-mediated T cell response that characterizes celiac. Yet they still react to wheat.

Several mechanisms have been proposed:

  • FODMAP fructans: A randomized crossover trial by Skodje et al. (2018) in Gastroenterology found that in most NCGS patients, the trigger was wheat FODMAPs (fructo-oligosaccharides) rather than gluten peptides themselves — suggesting many "gluten-sensitive" individuals are actually fructan-sensitive, which is a completely different mechanism.
  • Innate immune activation: Some research suggests that alpha-amylase trypsin inhibitors (ATIs) in modern wheat activate TLR4 on intestinal dendritic cells, triggering innate (non-adaptive) immune responses that don't require HLA presentation.
  • Wheat lectins: Wheat germ agglutinin binds to intestinal epithelial cells and may increase permeability independently of gluten.

The practical implication: a negative HLA-DQ2/DQ8 result does not mean wheat is not causing your symptoms. It means celiac disease is not the mechanism. NCGS, fructan sensitivity, wheat allergy, and non-immunological reactions to wheat are all possible explanations independent of HLA.

Monitoring and Associated Conditions

Celiac disease is not solely a gastrointestinal disease. Untreated celiac — or inadequately treated celiac — has systemic consequences driven by malabsorption and chronic autoimmune activation:

  • Bone density: Calcium and vitamin D malabsorption causes low bone mineral density in approximately 40% of newly diagnosed celiac patients. DEXA scan at diagnosis is recommended.
  • Iron deficiency anemia: Iron is preferentially absorbed in the proximal duodenum — the site of maximum villous damage in celiac. Iron-deficiency anemia is often the presenting finding in adults.
  • Neurological manifestations (gluten ataxia): Anti-tTG6 antibodies target the cerebellum; some celiac patients present with progressive ataxia rather than GI symptoms. Strictly gluten-free diet can stabilize or improve ataxia if started before irreversible damage.
  • Dermatitis herpetiformis: An intensely itchy papulovesicular skin rash driven by IgA anti-tTG deposits in the skin — the dermatological manifestation of celiac disease. Present without GI symptoms in some patients.
  • Associated autoimmune conditions: Type 1 diabetes, Hashimoto's thyroiditis, Sjogren's syndrome, and primary biliary cholangitis all occur at higher rates in celiac patients, likely due to shared immune genetic architecture.

Protocol by HLA Status

Neither DQ2 nor DQ8

  • Celiac disease is not the explanation for any wheat-related symptoms — investigate NCGS, fructan sensitivity, wheat allergy, or functional GI mechanisms
  • No restriction of gluten needed for celiac prevention regardless of family history
  • If wheat still causes symptoms, consider low-FODMAP trial or IgE testing for wheat allergy

DQ2 or DQ8 Positive (No Current Symptoms)

  • Annual tTG-IgA serology if first-degree relative has celiac disease (10x higher risk than general population)
  • Maintain adequate vitamin D, iron, calcium, and B12 intake given future malabsorption risk
  • Breastfeed infants where possible and introduce gluten early (4-6 months) per current evidence
  • Do not eliminate gluten prophylactically — there is no evidence this prevents disease and makes future diagnosis more difficult

Diagnosed Celiac Disease (DQ2/DQ8 Positive + Biopsy Confirmed)

  • Strict lifelong gluten-free diet (<20 ppm gluten): wheat, barley, rye, contaminated oats
  • Address micronutrient deficiencies: iron, B12, folate, vitamin D, zinc, copper, magnesium — test at diagnosis and 12 months post-diet
  • DEXA scan at diagnosis; repeat every 2-3 years until bone density normalizes
  • Vitamin D 2,000-5,000 IU/day + calcium 1,200mg/day until gut healing verified
  • Probiotic supplementation (Lactobacillus rhamnosus GG or Bifidobacterium infantis) may support mucosal healing and gut barrier repair
  • Monitor for thyroid disease and type 1 diabetes given autoimmune clustering

Know your HLA-DQ2/DQ8 status and understand your celiac risk and gluten sensitivity profile.

Analyze Your Genome →

References

Sollid LM et al. (2002)

Celiac disease: dissecting a complex inflammatory disorder. Nature Reviews Immunology. Foundational molecular mechanism review of HLA and gluten peptide presentation.

Fasano A (2012)

Leaky gut and autoimmune diseases. Clinical Reviews in Allergy and Immunology. Zonulin pathway and gluten-driven permeability in celiac.

Skodje GI et al. (2018)

Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology. The FODMAP vs. gluten distinction in NCGS.

Trynka G et al. (2011)

Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nature Genetics. Non-HLA celiac loci beyond DQ2/DQ8.

Lionetti E et al. (2014)

Introduction of gluten, HLA status, and the risk of celiac disease in children. New England Journal of Medicine. Gluten introduction timing and celiac risk in DQ2/DQ8 children.